(Q85217276)

English

Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study

scientific article published on 18 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

9

object named as

Didier Blaise

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Anne Etienne

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Raynier Devillier

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Emilie Romeo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Aude Charbonnier

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Evelyne D'incan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Benjamin Esterni

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Christine Arnoulet

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Norbert Vey

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

18 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

117

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

974-981

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed and refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Biology and management of relapsed acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and [...]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Clofarabine combinations as acute myeloid leukemia salvage therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and compa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25554

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25554

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20957721%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85217276&oldid=1587309736"